157 related articles for article (PubMed ID: 20500107)
1. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome.
Lindholm A; Bixo M; Eliasson M; Hudecova M; Arnadottir R; Holte J; Poromaa IS
Gynecol Endocrinol; 2010 Oct; 26(10):743-8. PubMed ID: 20500107
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.
Carmassi F; De Negri F; Fioriti R; De Giorgi A; Giannarelli C; Fruzzetti F; Pedrinelli R; Dell'Omo G; Bersi C
Thromb Res; 2005; 116(3):207-14. PubMed ID: 15935829
[TBL] [Abstract][Full Text] [Related]
3. Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system.
Sills ES; Drews CD; Perloe M; Tucker MJ; Kaplan CR; Palermo GD
Gynecol Endocrinol; 2003 Jun; 17(3):231-7. PubMed ID: 12857431
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A
Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652
[TBL] [Abstract][Full Text] [Related]
5. Effects of acupuncture and exercise on insulin sensitivity, adipose tissue characteristics, and markers of coagulation and fibrinolysis in women with polycystic ovary syndrome: secondary analyses of a randomized controlled trial.
Stener-Victorin E; Baghaei F; Holm G; Janson PO; Olivecrona G; Lönn M; Mannerås-Holm L
Fertil Steril; 2012 Feb; 97(2):501-8. PubMed ID: 22154367
[TBL] [Abstract][Full Text] [Related]
6. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.
Andersen P; Seljeflot I; Abdelnoor M; Arnesen H; Dale PO; Løvik A; Birkeland K
Metabolism; 1995 May; 44(5):611-6. PubMed ID: 7752909
[TBL] [Abstract][Full Text] [Related]
7. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome.
Mannerås-Holm L; Baghaei F; Holm G; Janson PO; Ohlsson C; Lönn M; Stener-Victorin E
J Clin Endocrinol Metab; 2011 Apr; 96(4):1068-76. PubMed ID: 21252248
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Glueck CJ; Sieve L; Zhu B; Wang P
Metabolism; 2006 Mar; 55(3):345-52. PubMed ID: 16483878
[TBL] [Abstract][Full Text] [Related]
9. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Wolczynski S; Gorska M
Hum Reprod; 2007 Jul; 22(7):1824-9. PubMed ID: 17582143
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
11. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
12. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
14. Long-term consequences of polycystic ovary syndrome on cardiovascular risk.
Rizzo M; Berneis K; Spinas G; Rini GB; Carmina E
Fertil Steril; 2009 Apr; 91(4 Suppl):1563-7. PubMed ID: 18976752
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome.
Palomba S; Orio F; Falbo A; Russo T; Tolino A; Zullo F
Fertil Steril; 2005 Sep; 84(3):761-5. PubMed ID: 16169420
[TBL] [Abstract][Full Text] [Related]
16. Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.
Koiou E; Tziomalos K; Dinas K; Katsikis I; Kandaraki EA; Tsourdi E; Mavridis S; Panidis D
Endocr J; 2012; 59(1):21-9. PubMed ID: 21996594
[TBL] [Abstract][Full Text] [Related]
17. Oxidative stress and inflammation in lean and obese subjects with polycystic ovary syndrome.
Blair SA; Kyaw-Tun T; Young IS; Phelan NA; Gibney J; McEneny J
J Reprod Med; 2013; 58(3-4):107-14. PubMed ID: 23539878
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator and plasma activator inhibitor-1 in young women with polycystic ovary syndrome.
Lin S; Yongmei G
Int J Gynaecol Obstet; 2008 Mar; 100(3):285-6. PubMed ID: 18029284
[No Abstract] [Full Text] [Related]
19. Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm.
Wanhainen A; Nilsson TK; Bergqvist D; Boman K; Björck M
J Vasc Surg; 2007 Jun; 45(6):1109-13. PubMed ID: 17543671
[TBL] [Abstract][Full Text] [Related]
20. [Regulators of fibrinolysis in chronic viral pathology of the liver].
Iagoda AV; Koroĭ PV
Ter Arkh; 2009; 81(2):50-4. PubMed ID: 19334490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
